Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kd Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

被引：0

作者：

Wang, Tingyu ^{[1
]}

Sun, Xiuhua ^{[2
]}

Qiu, Lihua ^{[3
]}

Su, Hang ^{[4
]}

Cao, Junning ^{[5
]}

Li, Zhiming ^{[6
]}

Song, Yuqin ^{[7
]}

Zhang, Li ^{[8
]}

Li, Dengju ^{[9
]}

Wu, Huijing ^{[10
]}

Zhang, Wei ^{[11
]}

Li, Junmin ^{[12
]}

Zhou, Keshu ^{[13
]}

Zhou, Hui ^{[14
]}

Yang, Yu ^{[15
]}

Li, Zhifeng ^{[16
,17
]}

Cen, Hong ^{[18
]}

Cai, Zhen ^{[19
]}

Zhang, Zhihui ^{[20
]}

Fu, Weijun ^{[21
]}

Jie, Jin ^{[22
]}

Li, Fei ^{[23
]}

Wu, Weixin ^{[24
]}

Gu, Xuekui ^{[25
]}

Zhu, Weiliang ^{[26
]}

Liu, Lihong ^{[27
]}

Li, Zengjun ^{[1
]}

Yi, Shuhua ^{[28
]}

Bao, Hanying ^{[29
]}

Xu, Zusheng ^{[29
]}

Qiu, Lugui ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Natl Clin Res Ctr Bloo, Tianjin, Peoples R China

[2] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[3] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc,Key Lab Canc Prevent &, Tianjin, Peoples R China

[4] Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China

[5] Fudan Univ, Dept Lymphoma, Shanghai Canc Ctr, Shanghai, Peoples R China

[6] State Key Lab Oncol South China, Guangzhou, Peoples R China

[7] Peking Univ Canc Hosp & Inst, Minist Educ, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China

[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China

[9] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China

[10] Hubei Canc Hosp, Wuhan, Peoples R China

[11] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Beijing, Peoples R China

[12] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China

[13] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[14] Cent South Univ, Xiangya Sch Med, Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China

[15] Fujian Med Univ, Tumor Hosp, Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[16] Xiamen Univ, Affiliated Hosp 1, Dept Hematol, Xiamen, Peoples R China

[17] Xiamen Univ, Sch Med, Inst Hematol, Xiamen, Peoples R China

[18] Guangxi Med Univ, Tumor Hosp, Nanning, Peoples R China

[19] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[20] Sichuan Canc Hosp & Inst, Chengdu, Peoples R China

[21] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Shanghai, Peoples R China

[22] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[23] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[24] Xiamen Univ, Zhongshan Hosp, Xiamen, Peoples R China

[25] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[26] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China

[27] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China

[28] Tianjin Inst Hlth Sci, Tianjin, Peoples R China

[29] Shanghai Yingli Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177820

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
Tao, Rong
Fan, Lei
Song, Yongping
Hu, Yu
Zhang, Wei
Wang, Yafei
Xu, Wei
Li, Jianyong
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[32] An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma
Izutsu, Koji
Makita, Shinichi
Nosaka, Kisato
Yoshimitsu, Makoto
Utsunomiya, Atae
Kusumoto, Shigeru
Morishima, Satoko
Tsukasaki, Kunihiro
Kawamata, Toyotaka
Ono, Takaaki
Rai, Shinya
Katsuya, Hiroo
Ishikawa, Jun
Yamada, Hironori
Kato, Kazunobu
Tachibana, Masaya
Kakurai, Yasuyuki
Adachi, Nobuaki
Tobinai, Kensei
Yonekura, Kentaro
Ishitsuka, Kenji
BLOOD, 2023, 141 (10) : 1159 - 1168
[33] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
Baiocchi, Robert A.
Alinari, Lapo
Lustberg, Mark E.
Lin, Thomas S.
Porcu, Pierluigi
Li, Xiaobai
Johnston, Jeffrey S.
Byrd, John C.
Blum, Kristie A.
CANCER, 2011, 117 (11) : 2442 - 2451
[34] Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
Rong Tao
Lei Fan
Yongping Song
Yu Hu
Wei Zhang
Yafei Wang
Wei Xu
Jianyong Li
Signal Transduction and Targeted Therapy, 6
[35] Coastal: A Phase 3 Study of the PI3Kd Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Jurczak, Wojciech
Zinzani, Pier Luigi Luigi
Cunningham, David
Azoulay, Michel
Huang, Wenying
Xu, Weiming
Ribrag, Vincent
BLOOD, 2021, 138
[36] Coastal: A phase 3 study of the PI3Kd inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL).
Jurczak, Wojciech
Zinzani, Pier Luigi
Cunningham, David
Yavrom, Sharon
Huang, Wenying
Gorbatchevsky, Igor
Ribrag, Vincent
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Xu, Wei
Yang, Shenmiao
Zhou, Keshu
Pan, Ling
Li, Zengjun
Zhou, Jianfeng
Gao, Sujun
Zhou, Daobin
Hu, Jianda
Feng, Ru
Huang, Haiwen
Ji, Meng
Guo, Haiyi
Huang, Jane
Novotny, William
Feng, Shibao
Li, Jianyong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
[38] Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study
Wei Xu
Shenmiao Yang
Keshu Zhou
Ling Pan
Zengjun Li
Jianfeng Zhou
Sujun Gao
Daobin Zhou
Jianda Hu
Ru Feng
Haiwen Huang
Meng Ji
Haiyi Guo
Jane Huang
William Novotny
Shibao Feng
Jianyong Li
Journal of Hematology & Oncology, 13
[39] Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Morschhauser, Franck
Tilly, Herve
Chaidos, Aristeidis
Phillips, Tycel J.
Ribrag, Vincent
Campbell, Philip
Laurent, Damaj Gandhi
Jurczak, Wojciech
McKay, Pamela
Opat, Stephen
Radford, John
Whalen, Jennifer
Rajarethinam, Anand
Navia, Susan Benedict
Adib, Deyaa
Salles, Gilles
BLOOD, 2019, 134
[40] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Johnston, Patrick B.
Pinter-Brown, Lauren
Rogerio, Jaqueline
Warsi, Ghulam
Graham, Anne
Ramchandren, Radhakrishnan
BLOOD, 2011, 118 (21) : 1169 - 1169

← 1 2 3 4 5 →